SLC2A3 and cancer: Upregulation of glucose transporters such as GLUT1 and GLUT3 constitutes a signature of cancer, which is used as a diagnosis with FDG-PET, but this overexpression is also associated with aggressiveness and invasiveness of tumors [35].